Eckert & Ziegler Expands Collaboration with GlyTherix to Supply Actinium-225 for Clinical Trials

• Eckert & Ziegler has expanded its collaboration with GlyTherix Ltd, securing a global supply agreement for Actinium-225 (Ac-225).

• The supply will support GlyTherix’s clinical research and development of innovative alpha radiotherapeutics for treating aggressive cancers.

Eckert & Ziegler has signed a global supply agreement with GlyTherix Ltd to provide Actinium-225 (Ac-225) in support of the latter’s clinical research and development of targeted radiotherapy. This collaboration extends the companies’ existing partnership, which is focused on Lutetium-177-based therapies, to include Ac-225, a key isotope for targeted alpha radiotherapy.

Ac-225 is critical in the development of novel cancer therapies due to its ability to deliver localized radiation to tumors while sparing healthy tissue. GlyTherix plans to use this isotope in its ongoing research, particularly targeting Glypican-1, a protein expressed in several aggressive cancers such as prostate, pancreatic, bladder, and ovarian cancer.

The agreement follows Eckert & Ziegler’s announcement in December 2024 that it had begun producing Ac-225 in collaboration with the Nuclear Physics Institute of the Czech Academy of Sciences. The company is currently working on establishing GMP-quality manufacturing, with plans to finalize production by the first half of 2025. This expansion will significantly increase the global supply of Ac-225, a crucial step for supporting the growing demand for alpha-emitting radiopharmaceuticals.

“We are happy to extend our collaboration with GlyTherix to fully support the planned development activities also for Actinium-225-based radiopharmaceuticals,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler. He emphasized that increasing Ac-225 availability will accelerate clinical research and commercial applications, ultimately improving cancer treatment access worldwide.

Dr. Brad Walsh, CEO of GlyTherix, expressed the company’s satisfaction with the partnership, highlighting the importance of securing a reliable supply of Ac-225 for its clinical program. GlyTherix plans to begin Phase I trials in Australia in early 2025, with US-based Phase II trials scheduled for 2026.